BCLI - Brainstorm Cell Therapeutics, Inc.
0.84
-0.330 -39.286%
Share volume: 819,677
Last Updated: 07-18-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.44%
PREVIOUS CLOSE
CHG
CHG%
$1.17
-0.33
-0.28%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-14-2024 | 08-14-2024 | 11-14-2024 | 05-15-2025 | 08-14-2025 | 11-14-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | |||
| Operating expenses | 2.474 M | 2.982 M | 3.048 M | 3.089 M | 2.573 M | 2.047 M | |
| Selling general and admin | 1.513 M | 2.060 M | 2.003 M | 1.785 M | 1.453 M | 1.148 M | |
| Research and development | 961.000 K | 922.000 K | 1.045 M | 1.304 M | 1.120 M | 899.000 K | |
| Total expenses | 2.474 M | 2.982 M | 3.048 M | 3.089 M | 2.573 M | 2.047 M | |
| 20.53% | 2.21% | 1.35% | -16.70% | -20.44% | |||
| Operating income | -2.474 M | -2.982 M | -3.048 M | -3.089 M | -2.573 M | -2.047 M | |
| Ebit | -3.414 M | -2.571 M | -2.654 M | -2.910 M | -2.573 M | -2.047 M | |
| Pretax income | -3.414 M | -2.571 M | -2.654 M | -2.910 M | -2.903 M | -2.106 M | |
| -24.69% | 3.23% | 9.65% | -0.24% | -27.45% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -3.401 M | -2.541 M | -2.708 M | -2.864 M | -2.903 M | -2.106 M | |
| 25.29% | -6.57% | -5.76% | -1.36% | 27.45% |